Publications by authors named "M Chakravarthy"

Claim this Profile
A
An open-label study on ulotaront's effects on insulin-glucose regulation in schizophrenia patients with metabolic syndrome and prediabetes: Part I.
Snezana Milanovic, Robert Lew, Kuangnan Xiong, Emily Casavant, Gerard Galluppi, Manu Chakravarthy

Diabetes Obes Metab· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A double-blind study on ulotaront's impact on weight-related parameters in schizophrenia patients with metabolic syndrome and prediabetes: Part II.
Snezana Milanovic, Robert Lew, Kuangnan Xiong, Emily Casavant, Gerard Galluppi, Manu Chakravarthy

Diabetes Obes Metab· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of CT-388, a once-weekly signaling-biased dual GLP-1/GIP receptor agonist, on weight loss and glycemic control in preclinical models and participants with obesity.
Manu V Chakravarthy, Ruben Rodriguez, Anne Hergarden, Michael A Elliott, Juan P Frias

Mol Metab· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of CT-868, a novel, fully biased, dual glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor agonist, in type 2 diabetes: A double-blind, randomized placebo controlled phase 2 trial.
Manu V Chakravarthy, Michael A Elliott, Luis Acosta, Gabriele E Sonnenberg, Damian Bialonczyk

Diabetes Obes Metab· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biased agonism of GLP-1R and GIPR enhances glucose lowering and weight loss, with dual GLP-1R/GIPR biased agonism yielding greater efficacy.
Ruben Rodriguez, Anne Hergarden, Shyam Krishnan, Marikris Morales, Davina Lam, Manu V Chakravarthy

Cell Rep Med· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis